bcdiabetes.ca
Patient Care + Research + Clinical Trials

Dr. Tom Elliott MBBS, FRCPC
Medical Director

400 - 210 W Broadway
Vancouver, BC
V5Y 3W2 Canada

phone: 604.683.3734
fax: 604.628.3821
email: moa@bcdiabetes.ca

SURPASS (Comparing Tirzepatide VS Dulaglutide on major adverse CV events in T2DM patients)

Study location: BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2
Principal Investigator Dr. Tom Elliott
Study coordinator & primary contact Dr. Hector Com P: 604-628-2395 : hcom@bcdiabetes.ca

Summary:
SURPASS is a phase III double-blind, active comparator, parallel-group RCT comparing the effect of weekly Tirzepatide versus Dulaglutide on CV outcomes when added to the standard of care in T2DM patients with established CV disease and elevated risk for a major adverse cardiovascular event.

Hypothesis:
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP1) receptor agonist. Previous phase 2b studies suggested better A1c control, with greater weight loss with Tirzepatide compared to Dulaglutide. Additionally, Tirzepatide showed a marked reduction of serum triglycerides concentrations (a CV risk factor in T2DM)

Eligible Participants include:

- Male or female at least 40 years old with T2DM.
- Established CVD, including coronary artery, cerebrovascular & peripheral arterial disease.
- A1c 7.0-10.5 & BMI >25
- Not on semaglutide, liraglutide, dulaglutide, linagliptin, saxagliptin, sitagliptin or alogliptin in last 3/12.

Treatment course and duration:
This is a CV outcomes driven trial planned to last for 5 years, through which Tirzepatide or Dulaglutide will be randomly assigned to all patients from visit 2 til the end of the study at no cost to them.

Tirzepatide will be initially given at a dose of 2.5 mg weekly to be escalated every 4 weeks to the maximum tolerated dose and up to 15 mg. Dose of 1.5 mg of Dulaglutide will remain unchanged throughout the study.

Clinic visits will be scheduled every 2 weeks for the first 6 months and every 3 months thereafter.
Visits include physical examination, blood and urine sampling, ECG, and referral to the eye specialist.

Odds of receiving placebo:
No placebo in this study. The odds of getting tirzepatide are 50%; the odds of getting dulaglutide are 50%.

Study documents:
Protocol
Ethics Approval
informed consent form (ICF)
shortURL = https://bit.ly/38VX2pn